ID | 57354 |
フルテキストURL | |
著者 |
Takahashi, Yuko
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
Iwamoto, Takayuki
Departments of Breast and Endocrine Surgery, Okayama University Hospital
Kaken ID
researchmap
Suzuki, Yoko
Departments of Breast and Endocrine Surgery, Okayama University Hospital
ORCID
Kajiwara, Yukiko
Departments of Breast and Endocrine Surgery, Okayama University Hospital
Hatono, Minami
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
Tsukioki, Takahiro
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
Kawada, Kengo
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
Kochi, Mariko
Departments of Breast and Endocrine Surgery, Okayama University Hospital
Ikeda, Hirokuni
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
Shien, Tadahiko
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Kaken ID
publons
researchmap
Taira, Naruto
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
Kaken ID
publons
Matsuoka, Junji
Departments of Palliative and Supportive Medicine, Okayama University Hospital
Kaken ID
researchmap
Doihara, Hiroyoshi
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
Toyooka, Shinichi
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Kaken ID
publons
researchmap
|
抄録 | Introduction
Patients with residual disease usually have a poor prognosis after neoadjuvant chemotherapy for breast cancer. The aim of this study was to explore therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy.
Patients and Methods
We retrieved publicly available complementary DNA microarray data from 399 human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer samples from patients who underwent standard neoadjuvant chemotherapy. We analyzed the messenger RNA (mRNA) expression levels of key breast cancer markers and therapeutic target genes according to residual cancer burden (RCB) classification: RCB-0/I, RCB-II, and RCB-III.
Results
Among hormone receptor–positive samples, there were more luminal A tumors by PAM50 (Prediction Analysis of Microarray 50 [Prosigna], aka Prosigna Breast Cancer Prognostic Gene Signature Assay) in RCB-III than in RCB-0/I and RCB-II (P < .01). The mRNA expressions of ESR1 and PGR were significantly higher, and that of MKI67 was lower in RCB-II and RCB-III than in RCB-0/I. The mRNA expression of cyclin D1 was up-regulated in RCB-III and that of CDKN2A was down-regulated in RCB-III (P = .027 and < .01). Among triple-negative (TN) samples, RCB-III had higher clinical stage and more lymph node–positive samples than RCB-0/1 and RCB-II (P < .01). In both subtypes, VEGF-C expression was significantly higher in RCB-III than in RCB-0/I and RCB-II.
Conclusion
In hormone receptor–positive breast cancer, biological features such as luminal A were associated with RCB; this trend was not observed in TN breast cancer. Further, some targeted therapies should be tested as new strategies after standard neoadjuvant chemotherapy in future clinical trials.
|
キーワード | Gene expression
Hormone receptor positive
Residual tumor burden
Targeted therapy
Triple negative
|
発行日 | 2020-04
|
出版物タイトル |
Clinical Breast Cancer
|
巻 | 20巻
|
号 | 2号
|
出版者 | Elsevier
|
開始ページ | 117
|
終了ページ | 124
|
ISSN | 1526-8209
|
NCID | AA11694891
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
論文のバージョン | author
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1016/j.clbc.2019.07.001
|